» Articles » PMID: 11555679

Articular Chondrocytes from Animals with a Dermatan Sulfate Storage Disease Undergo a High Rate of Apoptosis and Release Nitric Oxide and Inflammatory Cytokines: a Possible Mechanism Underlying Degenerative Joint Disease in the Mucopolysaccharidoses

Overview
Journal Lab Invest
Specialty Pathology
Date 2001 Sep 14
PMID 11555679
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Mucopolysaccharidosis (MPS) Type VI (Maroteaux-Lamy Disease) is the lysosomal storage disease characterized by deficient arylsulfatase B activity and the resultant accumulation of dermatan sulfate-containing glycosaminoglycans (GAGs). A major feature of this and other MPS disorders is abnormal cartilage and bone development leading to short stature, dysostosis multiplex, and degenerative joint disease. To investigate the underlying cause(s) of degenerative joint disease in the MPS disorders, articular cartilage and cultured articular chondrocytes were examined from rats and cats with MPS VI. An age-progressive increase in the number of apoptotic chondrocytes was identified in the MPS animals by terminal transferase nick-end translation (TUNEL) staining and by immunohistochemical staining with anti-poly (ADP-ribose) polymerase (PARP) antibodies. Articular chondrocytes grown from these animals also released more nitric oxide (NO) and tumor necrosis factor alpha (TNF-alpha) into the culture media than did control chondrocytes. Notably, dermatan sulfate, the GAG that accumulates in MPS VI cells, induced NO release from normal chondrocytes, suggesting that GAG accumulation was responsible, in part, for the enhanced cell death in the MPS cells. Coculture of normal chondrocytes with MPS VI cells reduced the amount of NO release, presumably because of the release of arylsulfatase B by the normal cells and reuptake by the mutant cells. As a result of the enhanced chondrocyte death, marked proteoglycan and collagen depletion was observed in the MPS articular cartilage matrix. These results demonstrate that MPS VI articular chondrocytes undergo cell death at a higher rate than normal cells, because of either increased levels of dermatan sulfate and/or the presence of inflammatory cytokines in the MPS joints. In turn, this leads to abnormal cartilage matrix homeostasis in the MPS individuals, which further exacerbates the joint deformities characteristic of these disorders.

Citing Articles

Evaluation of etanercept (a tumor necrosis factor alpha inhibitor) as an effective treatment for joint disease in mucopolysaccharidosis type I. A case report with whole-body magnetic resonance imaging.

Buchinskaya N, Isupova E, Vechkasova A, Malekov D, Ivanov D, Kostik M Front Med (Lausanne). 2024; 10:1252704.

PMID: 38314027 PMC: 10834648. DOI: 10.3389/fmed.2023.1252704.


Reduction of lysosome abundance and GAG accumulation after odiparcil treatment in MPS I and MPS VI models.

Tuyaa-Boustugue P, Jantzen I, Zhang H, Young S, Broqua P, Tallandier M Mol Genet Metab Rep. 2023; 37:101011.

PMID: 38053941 PMC: 10694777. DOI: 10.1016/j.ymgmr.2023.101011.


Enhanced Efficiency of the Basal and Induced Apoptosis Process in Mucopolysaccharidosis IVA and IVB Human Fibroblasts.

Brokowska J, Gaffke L, Pierzynowska K, Wegrzyn G Int J Mol Sci. 2023; 24(18).

PMID: 37762422 PMC: 10531891. DOI: 10.3390/ijms241814119.


Growth patterns in patients with mucopolysaccharidosis VII.

Montano A, Rozdzynska-Swiatkowska A, Jurecka A, Ramirez A, Zhang L, Marsden D Mol Genet Metab Rep. 2023; 36:100987.

PMID: 37415957 PMC: 10320588. DOI: 10.1016/j.ymgmr.2023.100987.


Leukocyte Imbalances in Mucopolysaccharidoses Patients.

Lopes N, Maia M, Pereira C, Mondragao-Rodrigues I, Martins E, Ribeiro R Biomedicines. 2023; 11(6).

PMID: 37371793 PMC: 10296078. DOI: 10.3390/biomedicines11061699.